Tocqueville Asset Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,584
| Closed | -$128K | – | 698 |
|
|
2022
Q1 | $128K | Sell |
1,584
-1,426
| -47% | -$211K | ﹤0.01% | 687 |
|
|
2021
Q4 | $610K | Sell |
3,010
-204
| -6% | -$44.3K | 0.01% | 525 |
|
|
2021
Q3 | $866K | Buy |
3,214
+640
| +25% | +$154K | 0.01% | 465 |
|
|
2021
Q2 | $662K | Sell |
2,574
-393
| -13% | -$109K | 0.01% | 505 |
|
|
2021
Q1 | $890K | Sell |
2,967
-4,927
| -62% | -$1.53M | 0.01% | 459 |
|
|
2020
Q4 | $2.01M | Sell |
7,894
-86
| -1% | -$22.2K | 0.03% | 345 |
|
|
2020
Q3 | $1.99M | Sell |
7,980
-943
| -11% | -$297K | 0.04% | 310 |
|
|
2020
Q2 | $3.1M | Sell |
8,923
-2,827
| -24% | -$882K | 0.06% | 256 |
|
|
2020
Q1 | $3.15M | Sell |
11,750
-591
| -5% | -$183K | 0.08% | 223 |
|
|
2019
Q4 | $4M | Sell |
12,341
-1,558
| -11% | -$452K | 0.06% | 278 |
|
|
2019
Q3 | $3.8M | Buy |
13,899
+1,324
| +11% | +$486K | 0.05% | 288 |
|
|
2019
Q2 | $6.71M | Sell |
12,575
-3,044
| -19% | -$1.53M | 0.09% | 241 |
|
|
2019
Q1 | $7.87M | Sell |
15,619
-5,410
| -26% | -$3.21M | 0.11% | 211 |
|
|
2018
Q4 | $10.4M | Buy |
21,029
+7,224
| +52% | +$4.36M | 0.16% | 164 |
|
|
2018
Q3 | $12.6M | Buy |
13,805
+3,586
| +35% | +$3.06M | 0.16% | 165 |
|
|
2018
Q2 | $7.49M | Buy |
10,219
+4,966
| +95% | +$5.73M | 0.1% | 223 |
|
|
2018
Q1 | $8.37M | Sell |
5,253
-15,284
| -74% | -$19.7M | 0.11% | 204 |
|
|
2017
Q4 | $18.4M | Buy |
20,537
+3,724
| +22% | +$2.2M | 0.21% | 129 |
|
|
2017
Q3 | $6.05M | Buy |
16,813
+1,320
| +9% | +$413K | 0.07% | 282 |
|
|
2017
Q2 | $4.54M | Sell |
15,493
-134
| -0.9% | -$38.7K | 0.05% | 309 |
|
|
2017
Q1 | $5.5M | Buy |
15,627
+2,257
| +17% | +$507K | 0.07% | 274 |
|
|
2016
Q4 | $2.46M | Buy |
13,370
+8,850
| +196% | +$1.8M | 0.03% | 387 |
|
|
2016
Q3 | $1.17M | Sell |
4,520
-4,460
| -50% | -$1.15M | 0.01% | 486 |
|
|
2016
Q2 | $1.92M | Sell |
8,980
-283
| -3% | -$63.3K | 0.02% | 418 |
|
|
2016
Q1 | $1.91M | Buy |
9,263
+753
| +9% | +$145K | 0.03% | 404 |
|
|
2015
Q4 | $2.15M | Buy |
8,510
+2,263
| +36% | +$465K | 0.03% | 411 |
|
|
2015
Q3 | $1.03M | Sell |
6,247
-6,240
| -50% | -$1.1M | 0.01% | 562 |
|
|
2015
Q2 | $2.34M | Sell |
12,487
-640
| -5% | -$110K | 0.03% | 439 |
|
|
2015
Q1 | $2.17M | Buy |
13,127
+7,734
| +143% | +$1.59M | 0.03% | 467 |
|
|
2014
Q4 | $1.25M | Buy |
5,393
+40
| +0.7% | +$8.55K | 0.01% | 541 |
|
|
2014
Q3 | $969K | Buy |
5,353
+1,886
| +54% | +$361K | 0.01% | 513 |
|
|
2014
Q2 | $667K | Buy |
3,467
+467
| +16% | +$82.6K | 0.01% | 656 |
|
|
2014
Q1 | $545K | Buy |
3,000
+333
| +12% | +$65.9K | 0.01% | 554 |
|
|
2013
Q4 | $454K | Buy |
2,667
+334
| +14% | +$53.9K | 0.01% | 600 |
|
|
2013
Q3 | $366K | Hold |
2,333
| – | – | ﹤0.01% | 720 |
|
|
2013
Q2 | $404K | Buy |
+2,333
| New | +$358K | 0.01% | 693 |
|
Other funds holding NKTR
MC
GPP
Tocqueville Asset Management's NKTR Position: Q2 2022 in Review
Tocqueville Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 1,584 shares — an estimated $128K sold.
Tocqueville Asset Management first reported a position in NKTR in Q2 2013 and held it in 36 quarters. The position peaked at $18.4M in Q4 2017. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.
- Tocqueville Asset Management reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
- Tocqueville Asset Management sold 1,584 Nektar Therapeutics shares in Q2 2022, an estimated $128K.
- Tocqueville Asset Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 36 quarters.
- Tocqueville Asset Management's Nektar Therapeutics position peaked at $18.4M in Q4 2017.
- 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.
Based on Tocqueville Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.